Pancreas & Biliary · Article 83

Who With Cirrhosis Requires Hepatocellular Carcinoma Surveillance?

HCC surveillance requires a structured, evidence-based clinical approach. This review summarizes the key diagnostic, management, monitoring and decision points for gastroenterology and hepatology practice.

HCC surveillance clinical reference — Related free clinical resource: Guideline-Based Management in Hepatology.

HCC surveillance: practical clinical approach

This page focuses on HCC surveillance with emphasis on decisions that change patient care, common pitfalls, and the current evidence base.

External guidance for HCC surveillance

Clinical takeaway: For HCC surveillance, decisions should integrate current guidelines, patient-specific risk, and the evidence summarized below.

Answer in brief: Most patients with Child-Pugh A or B cirrhosis who would be candidates for HCC treatment should undergo surveillance every six months. AASLD recommends ultrasound plus AFP as the standard surveillance strategy. Surveillance is generally not useful in Child-Pugh C cirrhosis unless the patient is a transplant candidate. Selected patients with chronic hepatitis B require surveillance even without cirrhosis because HBV itself confers HCC risk.

Key clinical points

Six-month surveillance is standard for appropriate cirrhosis patients.
Ultrasound plus AFP is the AASLD-recommended baseline strategy.
Poor ultrasound visualization may justify MRI- or CT-based surveillance in selected patients.
Non-cirrhotic MASLD alone is not currently an AASLD indication for routine HCC surveillance.

Who benefits

Surveillance is worthwhile when the patient’s HCC risk is sufficiently high and they could receive potentially beneficial treatment if cancer is detected. Most patients with compensated cirrhosis meet that criterion regardless of the underlying cause.

Who may not benefit

Patients with severe competing illness or Child-Pugh C cirrhosis who are not transplant candidates may not benefit because early HCC detection is unlikely to change outcome. Surveillance should therefore be tied to treatment candidacy, not performed automatically forever.

How to screen

AASLD recommends abdominal ultrasound with AFP every six months. Shorter intervals have not clearly improved outcomes, while annual surveillance is less effective. If ultrasound quality is repeatedly limited—for example, in severe obesity or markedly nodular liver—contrast-enhanced MRI or multiphasic CT may be considered based on patient factors and local practice.

HBV without cirrhosis

Selected chronic hepatitis B populations remain at sufficient HCC risk to warrant surveillance even without cirrhosis. Risk depends on age, sex, ancestry, family history and viral factors; HBV surveillance therefore requires disease-specific assessment.

Practical approach

1. Confirm that the patient belongs to a surveillance-risk group and could receive HCC treatment.

2. Use ultrasound plus AFP every 6 months when visualization is adequate.

3. Escalate abnormal surveillance findings to diagnostic multiphasic CT or MRI.

4. Reconsider the modality when ultrasound quality is repeatedly limited.

Common errors to avoid

Performing annual rather than six-month surveillance in an eligible cirrhosis patient.
Continuing surveillance when severe competing illness means HCC treatment would never be offered.

Trainee takeaway

Most patients with Child-Pugh A or B cirrhosis who would be candidates for HCC treatment should undergo surveillance every six months. The examination question is usually less about memorizing one cutoff than recognizing which finding changes the next clinical decision.

Frequently asked questions

Should every patient with MASLD get HCC screening?

No. AASLD does not recommend routine surveillance for non-cirrhotic MASLD.

Why every six months?

This interval balances tumor growth biology, detection performance and evidence that surveillance can identify cancers at a more treatable stage.

References

1. Thomson ABR. Guideline-Based Management in Hepatology. CAPstone Academic Publishers; 2015. ISBN 978-1502928078.

2. Thomson ABR. Best Practice Guidelines in Hepatopancreaticobiliary Disorders. CAPstone Academic Publishers; 2024. ISBN 979-8861272735.

3. Singal AG, Llovet JM, Yarchoan M, et al. AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology. 2023;78:1922-1965. doi:10.1097/HEP.0000000000000466.

Editorial note: This educational article synthesizes Dr. Thomson’s teaching framework with current society guidance. Recommendations should be checked against the latest guideline, local formulary, regulatory labeling and the individual clinical context before patient-specific use.

← Back to Clinical Questions